Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Nitrendipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F known ✓ | O60840 | 9/20 | 0.91 |
| ▸ | CACNA1D known ✓ | Q01668 | 9/20 | 0.91 |
| ▸ | CACNA1S known ✓ | Q13698 | 9/20 | 0.91 |
| ▸ | CACNA1C known ✓ | Q13936 | 9/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Nitrendipine SCHEMBL38973 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL29465067 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL15516493 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL38972 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| (S)-Nitrendipine SCHEMBL120983 | 1.00 | HIF1A (1.00) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL28250729 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL27589897 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL10914240 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL28360428 | 0.99 | HIF1A (0.98) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 | |
| Nitrendipine SCHEMBL23647366 | 0.96 | HIF1A (0.92) | HIF1AMEN1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744654-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | Anavex Life Sciences Corp. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250281447-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. | 2025-09-11 | — | — | US | disclosed |
| US-12280034-B2 | Sigma-1 receptor agonist systolic blood pressure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2025-04-22 | — | — | US | disclosed |
| US-11622955-B2 | Sigma-1 receptor agonist systolic blood pressure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230071766-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2023-03-09 | — | — | US | disclosed |